Literature DB >> 28688275

Design and synthesis of conformationally constrained salinomycin derivatives.

Wenxuan Zhang1, Jun Wu2, Bo Li3, Xu Lian3, Jie Xia3, Qi Zhou2, Song Wu4.   

Abstract

Two conformationally restricted salinomycin derivatives by tethering the hydroxyl groups at C1 and C20 with different chain length were designed and synthesized. The cyclic derivatives showed better biological activities than C1/C20 modified derivatives, indicating the importance of the compact conformation for the ion binding capacity. In addition, the length of the connective chain plays critical role in the biological activities, thus cyclic the derivative 7 preserved some pharmacological activity but derivative 5 with two carbon atom shorter chain showed significantly reduced activity. The conformations of the two cyclic salinomycin derivatives were analyzed by ROESY spectrum in DMSO-d6, indicating derivative 7 may adopt more appropriate conformations for the coordinate with alkali metal ion than derivative 5, which has a closer distance between H3 and H25.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti-cancer; Conformational restriction; Salinomycin

Mesh:

Substances:

Year:  2017        PMID: 28688275     DOI: 10.1016/j.ejmech.2017.06.063

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  3 in total

1.  Rapid Access to Ironomycin Derivatives by Click Chemistry.

Authors:  Michał Antoszczak; Sebastian Müller; Ludovic Colombeau; Tatiana Cañeque; Raphaël Rodriguez
Journal:  ACS Org Inorg Au       Date:  2022-01-21

Review 2.  Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers.

Authors:  Vivek Kaushik; Juan Sebastian Yakisich; Anil Kumar; Neelam Azad; Anand K V Iyer
Journal:  Cancers (Basel)       Date:  2018-09-27       Impact factor: 6.639

Review 3.  Salinomycin as a potent anticancer stem cell agent: State of the art and future directions.

Authors:  Dan Qi; Yunyi Liu; Juan Li; Jason H Huang; Xiaoxiao Hu; Erxi Wu
Journal:  Med Res Rev       Date:  2021-11-16       Impact factor: 12.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.